These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself. Tice AD; Poretz D; Cook F; Zinner D; Strauss MJ Clin Infect Dis; 1998 Dec; 27(6):1415-21. PubMed ID: 9868653 [TBL] [Abstract][Full Text] [Related]
3. A cost-effective approach to managing infectious disease. Wright RA Consultant; 1989 May; 29(5):143-6, 150, 155. PubMed ID: 10292917 [TBL] [Abstract][Full Text] [Related]
4. Business aspects of infectious diseases. Tenenbaum MJ; Petrak R Clin Infect Dis; 2002 Feb; 34(3):420. PubMed ID: 11774093 [No Abstract] [Full Text] [Related]
5. Computer-assisted evaluation of antibiotic regimen coverage and cost. Day D; Lubowski TJ; Yamaga CC; Main J; Van Vleet J; Ambegaonkar A Clin Ther; 1999 Aug; 21(8):1418-25. PubMed ID: 10485512 [TBL] [Abstract][Full Text] [Related]
6. The cost of antibiotic treatment for priority infectious syndromes in Paraguay, 2004. Baez E; Dentice MA; Heitmann I Epidemiol Bull; 2005 Jun; 26(2):8-11. PubMed ID: 16578882 [No Abstract] [Full Text] [Related]
7. Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. Parker SE; Nathwani D; O'Reilly D; Parkinson S; Davey PG J Antimicrob Chemother; 1998 Sep; 42(3):373-80. PubMed ID: 9786477 [TBL] [Abstract][Full Text] [Related]
11. Appropriate selection of antimicrobials in the treatment of ambulatory patients. Goetz MB Health Syst Lead; 1994 Oct; 1(8):34-8. PubMed ID: 10140124 [No Abstract] [Full Text] [Related]
12. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Bailey TC; Ritchie DJ; McMullin ST; Kahn M; Reichley RM; Casabar E; Shannon W; Dunagan WC Pharmacotherapy; 1997; 17(2):277-81. PubMed ID: 9085319 [TBL] [Abstract][Full Text] [Related]
14. Changing the focus of infectious diseases to pathogen-specific therapy. Zuger A Clin Infect Dis; 1997 Aug; 25(2):348-50. PubMed ID: 9332552 [No Abstract] [Full Text] [Related]
15. Challenges in the 2016 Medicare OPPS Proposed Rule. Kovar M Revenue-cycle Strateg; 2015 Oct; 12(8):1-4. PubMed ID: 26591899 [No Abstract] [Full Text] [Related]
16. Drug treatment of pneumonia in the elderly: efficacy and costs. Saltiel E; Weingarten S Pharmacoeconomics; 1993 Apr; 3(4):268-75. PubMed ID: 10146990 [No Abstract] [Full Text] [Related]
18. On the implications of endogenous resistance to medications. Laxminarayan R; Weitzman ML J Health Econ; 2002 Jul; 21(4):709-18. PubMed ID: 12146599 [TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Durojaiye OC; Bell H; Andrews D; Ntziora F; Cartwright K Int J Antimicrob Agents; 2018 Jan; 51(1):26-32. PubMed ID: 28673610 [TBL] [Abstract][Full Text] [Related]
20. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Ball AT; Xu Y; Sanchez RJ; Shelbaya A; Deminski MC; Nau DP Clin Ther; 2010 Dec; 32(13):2246-55. PubMed ID: 21316540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]